121 related articles for article (PubMed ID: 38700579)
1. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
Invest New Drugs; 2024 May; ():. PubMed ID: 38700579
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer.
Tan A; Wang H; Nong L; Jia Y; Liu Y; Zhong W; Qin F; Wang H; Tang J; Zhou W; Lu Y; Xie W
Ann Palliat Med; 2021 Dec; 10(12):12101-12112. PubMed ID: 35016411
[TBL] [Abstract][Full Text] [Related]
3. Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study.
Pu X; Wang Q; Liu L; Chen B; Li K; Zhou Y; Sheng Z; Liu P; Tang Y; Xu L; Li J; Kong Y; Xu F; Xu Y; Wu L
Cancer Med; 2023 Apr; 12(7):7724-7733. PubMed ID: 36494905
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
5. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer.
Qin ZQ; Yang SF; Chen Y; Hong CJ; Zhao TW; Yuan GR; Yang L; Gao L; Wang X; Lu LQ
World J Clin Cases; 2022 Feb; 10(4):1164-1171. PubMed ID: 35211549
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer.
Lv W; Pei X; Zhao W; Cong Y; Wei Y; Li T; Zhang H; Lin Z; Saito Y; Kim JJ; Liang Z; Zhong B; Wang Z
Transl Lung Cancer Res; 2022 Feb; 11(2):201-212. PubMed ID: 35280309
[TBL] [Abstract][Full Text] [Related]
7. Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study.
Zhao J; Cheng Y; He L; Wang J; Xi Q; Gong C
J Thorac Dis; 2022 Nov; 14(11):4416-4426. PubMed ID: 36524068
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of endostatin in combination with chemotherapy in small cell lung cancer: a phase 2 single-arm multicenter open-label trial.
Zhao Y; Zhang X; Jin C; Yu X; Zhang M; Cao Y; Li Y; Wang A; Shan X; Zhang J; Wang J; Yin L; Tan X; Liu J
Ann Palliat Med; 2021 Mar; 10(3):3277-3285. PubMed ID: 33849112
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
[TBL] [Abstract][Full Text] [Related]
12. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
16. Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study.
Wang X; Wang T; Chu Y; Liu J; Yi C; Yu X; Wang Y; Zheng T; Cao F; Qu L; Yu B; Liu H; Ding F; Wang S; Wang X; Hao J; Wang X
Front Oncol; 2023; 13():1089234. PubMed ID: 37007066
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer.
Lu S; Li L; Luo Y; Zhang L; Wu G; Chen Z; Huang C; Guo S; Zhang Y; Song X; Yu Y; Zhou C; Li W; Liao M; Li B; Xu L; Chen P; Hu C; Hu C
J Thorac Oncol; 2015 Jan; 10(1):206-11. PubMed ID: 25654728
[TBL] [Abstract][Full Text] [Related]
18. AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y; Chen G; Chen J; Zhuang L; Du Y; Yu Q; Zhuang W; Zhao Y; Zhou M; Zhang W; Zhang Y; Wan Y; Li W; Song W; Wang ZM; Li B; Xia M; Yang Y; Fang W; Huang Y; Zhang L
EClinicalMedicine; 2023 Aug; 62():102106. PubMed ID: 37593227
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer.
Chen L; Tong F; Peng L; Huang Y; Yin P; Feng Y; Cheng S; Wang J; Dong X
Radiother Oncol; 2022 Sep; 174():44-51. PubMed ID: 35788355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
